HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...
New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results